Lupin Limited has informed the Exchange regarding a press release dated October 13, 2025, titled "Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at theESMO Congress 2025".
Press Release Oct 13 2025
Filed with NSE ·
6ix hasn’t read this filing yet.
Earlier from Lupin
- Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the ESMO Congress 2025
- Press Release Oct 09 2025
- Lupin Unveils Strategic Partnership Program to Expand Reach of its Long-Acting Injectable Platform
- Press Release Oct 08 2025
- Lupin Announces Plans to Build a New State-of-the-Art Manufacturing Facility in Coral Springs, Florida Extending its Long-Standing Commitment to America's Patients and Healthcare System
Later from Lupin
- Kenox Pharmaceuticals Appoints Dr. Julianne Berry as Vice President of R&D and Manufacturing
- Press Release Oct 24 2025
- Governor Murphy and Local Leaders Attend Ribbon-Cutting Ceremony, Marking the Inauguration of Lupin's New Corporate Offices in Bridgewater
- Press Release Oct 28 2025
- Press Release Oct 30 2025
Follow Lupin into a list and get an email when it puts out news.
Follow Lupin